Sun Yat-sen University: Triple Negative Breast Neoplasms trials

The registry lists 10 Triple Negative Breast Neoplasms studies with Sun Yat-sen University as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 2 9Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• FMD and Neoadjuvant Chemo-immunotherapy in TNBCRecruitingNCT07378306Phase 2
• Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast CancerRecruitingNCT06768931Phase 2
• The Optimal Radioimmunotherapy Combinations for Advanced TNBCRecruitingNCT06735131Phase 2
• Arsenous Acid for Refractory Triple-Negative Breast CancerRecruitingNCT06678048Phase 2
• Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)Active, not recruitingNCT06618014Phase 2
• Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer PatientsCompletedNCT05632848Phase 2
• Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast CancerTerminatedNCT05300958Phase 2
• Evaluation of Epalrestat in Metastatic Triple-negative Breast CancerTerminatedNCT03244358Phase 2
• Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast CancerTerminatedNCT03055312Phase 3
• Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast CancerTerminatedNCT02183805Phase 2